Company Product Description Indication Status
Endo International plc, of Dublin Collagenase clostridium histolyticum Enzyme targeting collagen  Cellulite in the buttocks FDA accepted the BLA; PDUFA action date of July 6, 2020
Hope Biosciences Inc., of Houston HB-adMSCs Autologous, adipose-derived mesenchymal stem cells Alzheimer’s disease FDA approved the 24-patient phase I/II study
Kiniksa Pharmaceuticals Ltd., Hamilton, Bermuda Rilonacept  Fusion protein that blocks IL-1alpha and IL-1beta signaling Recurrent pericarditis FDA granted breakthrough therapy designation
Merck & Co. Inc., of Kenilworth, N.J. Keytruda (pembrolizumab) Monoclonal antibody targeting PD-1 Metastatic or unresectable recurrent head and neck squamous cell carcinoma expressing PD-L1 European Commission approved the expanded indication as a monotherapy or in combination with platinum and 5-fluorouracil chemotherapy
Merck KGaA, of Darmstadt, Germany Tepotinib MET inhibitor Non-small-cell lung cancer with MET gene alterations Japanese Ministry of Health, Labour and Welfare granted orphan drug designation
OWP Pharmaceuticals Inc., Naperville, Ill. Liquid formulation of topiramate Targets voltage-dependent sodium channels, GABA receptors and glutamate receptors Epilepsy and migraine FDA approved IND
Vertical Pharmaceuticals LLC, of Bridgewater, N.J. RVL-1201 Ophthalmic formulation of alpha-adrenergic receptor agonist oxymetazoline Acquired blepharoptosis FDA accepted the NDA; PDUFA action date of July 16, 2020

Notes

For more information about individual companies and/or products, see Cortellis.

No Comments